Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Drug switching"'
Autor:
Shuaiqi Chen, Guangyu Sun, Xiaoxu Chen, Tiyara Salgado, Shangrong Wu, Hailong Hu, Ranlu Liu, Yunkai Qie
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Objective To explore if switching intravesical chemotherapeutic agents is beneficial in short-term recurrences of high-risk non-muscle-invasive bladder cancer (NMIBC) following the failure of preceding intravesical therapy. Materials and met
Externí odkaz:
https://doaj.org/article/ee8f882ef0ea4f8087690be663b323da
Publikováno v:
Lipids in Health and Disease, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background Although generic drugs have been approved with the assurance of interchangeable applications with original drugs, some physicians, and patients still view their efficacy and interchangeability negatively. Using real-world data, we
Externí odkaz:
https://doaj.org/article/87ec246e857947c0afbb01a0f4a54054
Autor:
Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Makiko Mieno, Mamitaro Ohtsuki
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 6, Pp 1347-1360 (2023)
Abstract Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors. Methods This real-world setting study
Externí odkaz:
https://doaj.org/article/887e69b2209d4ab787684aca16a0167e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
In 2019, the U.S. Food and Drug Administration (FDA) approved emtricitabine and tenofovir alafenamide (Descovy) as another option for HIV pre-exposure prophylaxis (PrEP) prevention for high-risk adults and adolescents. With the introduction of this n
Externí odkaz:
https://doaj.org/article/3a15abe3366b4677ba048a70bc49fdc3
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-9 (2022)
Abstract Background Drug coverage policies that incentivize switching patients from originator to biosimilar products may result in significant health care savings. Our study aimed to detect early impacts on health services utilization following a ma
Externí odkaz:
https://doaj.org/article/45c0a9dff4bf429d972effef5136fc34
Autor:
Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, Florence Ajok, Henry Onen, Ivan Kalule, Phoebe Kajubi, Kay Seden, Noela Owarwo, Agnes Kiragga, Mari Armstrong-Hough, Anne Katahoire, Andrew Mujugira, Mohammed Lamorde, Barbara Castelnuovo
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to
Externí odkaz:
https://doaj.org/article/4e44c82667bb4af7ad5d72f67e6e462a
Autor:
Chung-Cheng Wang, Ming-Huei Lee, Yao-Chi Chuang, Yung-Shun Juan, Hsiang-Ying Lee, Wei-Yu Lin, Chun-Hou Liao, Hann-Chorng Kuo
Publikováno v:
Continence, Vol 4, Iss , Pp 100518- (2022)
Objectives:: We investigated the efficacy and safety of a transdermal oxybutynin patch in treating patients with overactive bladder (OAB). Methods:: Ninety-three adult patients with OAB who were under stable treatment with antimuscarinic agents, mira
Externí odkaz:
https://doaj.org/article/39416164a58246b0b9f47d2e201d3107
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.